Taken together, with our understanding of breast cancer subtypes and response with better and better imaging, it becomes our obligation to test the hypothesis that surgery can be safely eliminated among patients with documented pathologic responses, a practice that has been utilized in other solid organ malignancies. The rationale for avoidance of breast and nodal surgery can be simply stated as: patients would prefer to not have surgery at all if their breast cancer can be safely and effectively treated without it. Although surgical techniques have improved substantially in the last two decades, surgery still can have an adverse personal impact with respect to physical, psychosocial, and sexual well-being, as well as other well-described complications.5-7
The main obstacle and challenge, with the elimination of breast cancer surgery among exceptional responders with neoadjuvant systemic therapy, is that current imaging is not accurate to predict pCR without surgery. The concept of proceeding directly to radiotherapy without surgery among patients with a good clinical response is not new.1 Prior studies attempting to deliver radiotherapy among complete clinical responders without breast surgery resulted in unacceptably high local regional recurrence rates.8-15
The other major issues with these studies—besides utilizing selection based on clinical response—were limited use of breast imaging for selection of patients, and they were also prior to our basic understanding of subtype response, best available systemic regimens, and, certainly, optimized modern breast imaging. It is also interesting to note that, on average, a breast imaging radiologic complete response occurs in about 20% of patients with the triple-negative and HER2 phenotype receiving preoperative systemic therapy, yet about 50% of patients will be found to have a pCR.1 Evaluation of documented nodal metastases and response to therapy are also very poor, with negative predictive values between 29% and 81%.1 Therefore, in order to also eliminate axillary surgery, it might be best to begin with patients who do not have documented or clinically detectable nodal disease based on physical examination, and at the minimum, an ultrasound evaluation.
By collaborating with breast radiologists and integrating image-directed extensive vacuum-assisted biopsy following neoadjuvant therapy, it is our hypothesis that we can accurately identify patients with a pCR without residual ductal carcinoma in situ or invasive breast cancer. This is currently being tested in MD Anderson Cancer Center protocol PA 2014-1039.16 Patients on this study have triple-negative or HER2 positive breast cancer receiving standard neoadjuvant chemotherapy. This group of patients was selected as they are the most likely to have a dramatic response with eradication of disease. Furthermore, patients with a pCR are also known, not only to have an increased overall and disease-free survival, but specifically, very low local regional recurrence rates.17
In our latest evaluation, the 5-year local regional recurrence rates were significantly less than those without a pCR, and, in fact, was only 2.6% and 1.4% among patients with HER2-positive and triple-negative disease, respectively.17 Patients are eligible for this study if they present with cancers less than 5 cm, have a partial or complete imaging response, and vacuum-assisted biopsy (VAB) is performed with a 9G device with a minimum sampling of six cores. The trial has specific endpoints related to a comparison of VAB versus fine-needle aspiration and a combination compared with final surgical pathology excision histology. If this proves to be an accurate and safe methodology, the sometimes overwhelming physical and emotional side effects of breast cancer treatments would likely be dramatically improved. Patients would much prefer going home with a bandage than a surgical procedure on their breasts. Accrual to this study has been brisk, and with over half of the patients accrued, the preliminary results of this study have been so promising, that it is our expectation that we will begin accrual on a definitive trial later this year to eliminate surgery among exceptional responders with triple-negative and HER2-positive disease with documented complete pCR by VAB. This will be followed by standard whole breast radiotherapy. Internationally, several groups, multi-center organizations, and cooperative groups, have commenced or are planning similar studies.18,19
The past half-century has witnessed remarkable clinical advancements and increased survival based on clinical trials for patients with breast cancer. It can be expected that there will be continued improvements in breast cancer systemic agents that will continue to yield higher and higher pathologic complete responses. Therefore, it is intuitive to consider whether or not surgery is necessary among these types of patients. The physical and psychological morbidity of surgery, particularly among patients with a diagnosis of invasive breast cancer, is tremendous. The opportunity to potentially increase patients’ quality of life, without impacting their long-term health, is our obligation, and this necessitates designing trials to advance the field.
Affiliation: Henry M. Kuerer, MD, PhD, FACS, is from the University of Texas MD Anderson Cancer Center, Houston, TX.
Address correspondence to: Henry M. Kuerer, MD, PhD, FACS, MD Anderson Cancer Network, Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1400 Pressler St., Unit 1434, Houston, TX 77004. Phone: 713-745-5043; Fax: 713-792-4689. E-mail: email@example.com
Acknowledgements: Portions of this manuscript were presented at the 33rd Annual Miami Breast Cancer Conference March 10-13, 2016. This project was supported by the PH and Fay Etta Robinson Distinguished Professorship in Research endowment (HMK) and the National Institutes of Health (NIH) Cancer Center Support Grant (CA16672).
- van la Parra RF, Kuerer HM. Selective elimination of breast cancer surgery in exceptional responders: historical perspective and current trials. Breast Cancer Res. 2016;18(1):28. doi: 10.1186/ s13058-016-0684-6.
- Boughey JC, McCall LM, Ballman KV, et al. Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial. Ann Surg. 2014;260(4):608-614; discussion 614-606. doi: 10.1097/SLA.0000000000000924.
- Kuerer HM, Newman LA, Fornage BD, et al. Role of axillary lymph node dissection after tumor downstaging with induction chemotherapy for locally advanced breast cancer. Ann Surg Oncol. 1998;5(8):673-680.
- Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999;17(2):460-469.
- Al-Hilli Z, Thomsen KM, Habermann EB, Jakub JW, Boughey JC. Reoperation for Complications after Lumpectomy and Mastectomy for Breast Cancer from the 2012 National Surgical Quality Improvement Program (ACS-NSQIP). Ann Surg Oncol. 2015;22 Suppl 3:S459-469. doi: 10.1245/s10434-015-4741-7.
- Losken A, Pinell-White X, Hodges M, Egro FM. Evaluating outcomes after correction of the breast conservation therapy deformity. Ann Plast Surg. 2015;74 Suppl 4:S209-213. doi: 10.1097/SAP.0000000000000443.
- Cano SJ, Klassen AF, Scott AM, Cordeiro PG, Pusic AL. The BREAST-Q: further validation in independent clinical samples. Plast Reconstr Surg. 2012;129(2):293-302. doi: 10.1097/ PRS.0b013e31823aec6b.
- Daveau C, Savignoni A, Abrous-Anane S, et al. Is radiotherapy an option for early breast cancers with complete clinical response after neoadjuvant chemotherapy? Int J Radiat Oncol Biol Phys. 2011;79(5):1452-1459. doi: 10.1016/j.ijrobp.2010.01.003.
- De Lena M, Varini M, Zucali R, et al. Multimodal treatment for locally advanced breast cancer. Result of chemotherapy-radiotherapy versus chemotherapy-surgery. Cancer Clin Trials. 1981;4(3):229-236.
- Ellis P, Smith I, Ashley S, et al. Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer. J Clin Oncol. 1998;16(1):107-114.
- Mauriac L, MacGrogan G, Avril A, et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS). Ann Oncol. 1999;10(1):47-52.
- Perloff M, Lesnick GJ, Korzun A, et al. Combination chemotherapy with mastectomy or radiotherapy for stage III breast carcinoma: a Cancer and Leukemia Group B study. J Clin Oncol. 1988;6(2):261-269.
- Ring A, Webb A, Ashley S, et al. Is surgery necessary after complete clinical remission following neoadjuvant chemotherapy for early breast cancer? J Clin Oncol. 2003;21(24):4540-4545.
- Scholl SM, Pierga JY, Asselain B, et al. Breast tumour response to primary chemotherapy predicts local and distant control as well as survival. Eur J Cancer. 1995;31A(12):1969-1975.
- Touboul E, Buffat L, Lefranc JP, et al. Possibility of conservative local treatment after combined chemotherapy and preoperative irradiation for locally advanced noninflammatory breast cancer. Int J Radiat Oncol Biol Phys. 1996;34(5):1019-1028.
- Accuracy of image guided percutaneous sampling compared with surgery to evaluate eradication of breast cancer after preoperative chemotherapy. National Institute of Health. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/ NCT02455791 (2015).
- Swisher SK, Vila J, Tucker SL, et al. Locoregional control according to breast cancer subtype and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast-conserving therapy. Ann Surg Oncol. 2016;23(3):749-756. doi: 10.1245/s10434-015-4921-5.
- Heil J, Kummel S, Schaefgen B, et al. Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques. Br J Cancer. 2015;113(11):1565-1570. doi: 10.1038/bjc.2015.381.
- De Los Santos JF, Cantor A, Amos KD, et al. Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 17. Cancer. 2013;119(10):1776-1783. doi: 10.1002/cncr.27995.